During the past decade, UCLA Clinical and Translational Research Center (CTRC) conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Clinical and Translational Research Center (CTRC)" #1 sponsor was "University of California, Los Angeles" with 4 trials, followed by "Biogen" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Clinical and Translational Research Center (CTRC)" #1 collaborator was "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" with 1 trials as a collaborator, "National Institutes of Health (NIH)" with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "Seagen Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Clinical and Translational Research Center (CTRC)" are "Focal Segmental Glomerulosclerosis (FSGS)" (1 trials), "Hematological Malignancies" (1 trials), "Hodgkin's Disease" (1 trials), "Human Immunodeficiency Virus" (1 trials) and "Liver Fibrosis" (1 trials). Many other conditions were trialed in "UCLA Clinical and Translational Research Center (CTRC)" in a lesser frequency.

Most popular intervention types in "UCLA Clinical and Translational Research Center (CTRC)" are "Drug" (4 trials), "Biological" (2 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "25(OH)D3" (1 trials), "Azacitidine" (1 trials), "Brentuximab vedotin" (1 trials), "Epidural stimulation" (1 trials) and "Magrolimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Clinical and Translational Research Center (CTRC)" are 8 trials for "All" genders.

Currently, there are NaN active trials in "UCLA Clinical and Translational Research Center (CTRC)". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in UCLA Clinical and Translational Research Center (CTRC), undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Clinical and Translational Research Center (CTRC), 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".